We started our collaboration with Agilent Technologies, Inc. (NYSE: A) to address customer challenges within existing Biopharma bioanalytical workflows to meet the emerging needs of the growing biopharmaceutical industry. Under Terms of the Agreement, a Memorandum of Understanding (MOU), Protea, using Agilent instrumentation combined with its technology, has expanded its collaboration to develop workflows that focus on new methods for the field of metabolomics.
Memorial Sloan-Kettering Cancer Center
We entered into a collaborative research initiative with the Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer Institute (Dana-Farber) that uses Protea’s mass spectrometry imaging (MSI) technology to analyze cancer cells. The initial focus is early stage lung adenocarcinoma. The studies will apply Protea technology to generate molecular profiles of sub populations of cancer cells in tissue to improve the understanding of a cancer’s origin.
Protea entered into aco-marketing agreement with MatTek Corporation which enables Protea to include MatTek’s human cell based in vitro tissue models with Protea’s proprietarymolecular imaging services. MatTek is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models.
We entered into an exclusive license agreement with Yale University for new Mass Spectrometry Imaging (MSI) technology to improve the differential diagnosis of malignant melanoma. The technology was developed jointly by the laboratory of Rossitza Lazova, MD, Associate Professor of Dermatology and Pathology at Yale School of Medicine and Protea Biosciences.
We entered into a business collaboration with Protein Metrics Inc. a premier provider of software solutions for the comprehensive characterization of proteins, to advance our analytical capabilities for use in the development of protein biotherapeutics.
In the future, we will expand our proprietary methods for molecular imaging and bioanalytical workflows. By bringing new developments in sample analysis and instrumentation, our capacity to provide big data to researchers will continue to advance, to meet the needs of tomorrow’s scientists for better, more comprehensive molecular information